Influence of estrogen receptor α and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 3, 2006, Pages 462-467

  Van Duijnhoven, Fränzel J B ^a   Peeters, Petra H M ^a   Warren, Ruth M L ^b   Bingham, Sheila A ^c   Uitterlinden, André G ^d   Van Noord, Paulus A H ^a   Monninkhof, Evelyn M ^a   Grobbee, Diederick E ^a   Van Gils, Carla H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GENE PRODUCT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ESR1 GENE; FEMALE; GENE; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NETHERLANDS; PGR GENE; PRIORITY JOURNAL; QUESTIONNAIRE;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; LINEAR MODELS; MAMMOGRAPHY; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 33645502496     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0754     Document Type: Article

References (46)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
5. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
6. Christodoulakos GE, Lambrinoudaki FV, Panoulis KP, et al. The effect of various regimens of hormone replacement therapy on mammographice breast density. Maturitas 2003;45:109-18.
7. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
8. Kilicdag EB, Bagis T, Pourbagher A, Tarim E. Hormone replacement therapy and mammographic density. Int J Gynaecol Obstet 2004;86:56-8.
9. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22.
10. McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994;163:311-5.
11. Ozdemir A, Konus O, Nas T, Erbas G, Cosar S, Isik S. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet 1999;67:23-32.
12. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.
13. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
14. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6.
15. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
16. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod 1996;54:287-93.
17. Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 2003;68:761-70.
18. van Duijnhoven FJ, Bezemer ID, Peeters PH, et al. Polymorphisms in the estrogen receptor {α} gene and mammographic density. Cancer Epidemiol Biomarkers Prev 2005;14:2655-60.
19. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-70.
20. Cai Q, Shu XO, Jin F, et al. Genetic polymorphisms in the estrogen receptor α gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2003;12:853-9.
21. Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH. The estrogen receptor α gene and breast cancer risk (the Netherlands). Cancer Causes Control 2005;16:1195-202.
22. Shin A, Kang D, Nishio H, et al. Estrogen receptor α gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003;80:127-31.
23. Wedren S, Lovmar L, Humphreys K, et al. Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004;6:R437-49.
24. de Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 2002;99:12263-8.
25. de Vivo I, Hankinson SE, Colditz GA, Hunter DJ. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003;63:5236-8.
26. Feigelson HS, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1084-5.
27. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000;60:2348-50.
28. Spurdle AB, Hopper JL, Chen X, et al. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002;11:439-43.
29. Boker LK, van Noord PA, van der Schouw YT, et al. Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. Eur J Epidemiol 2001; 17:1047-53.
30. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80 Suppl 1:95-103.
31. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26: S6-14.
32. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, et al. The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. Int J Epidemiol 1997;26: S37-48.
33. Ocke MC, Bueno-de-Mesquita HB, Pols MA, Smit HA, Van Staveren WA, Kromhout D. The Dutch EPIC food frequency questionnaire. II. Relative validity and reproducibility for nutrients. Int J Epidemiol 1997;26:S49-58.
34. Byng JW, Boyd NF, Little L, et al. Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 1996;5:319-27.
35. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol 1994;39:1629-38.
36. Wareham NJ, Jakes RW, Rennie KL, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003;6:407-13.
37. Lord SJ, Mack WJ, Van Den BD, et al. Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Breast Cancer Res 2005;7:R336-44.
38. Lillie EO, Bernstein L, Ingles SA, et al. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res 2004;64:1237-41.
39. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-82.
40. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969-77.
41. Maruyama H, Toji H, Harrington CR, et al. Lack of an association of estrogen receptor α gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol 2000;57:236-40.
42. Agoulnik IU, Tong XW, Fischer DC, et al. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004;89:6340-7.
43. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26:1358-61.
44. Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. Measurements of breast density; no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 2005;14:2634-40.
45. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
46. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-8.